Negative results in recent trials have highlighted the challenges that newer genomic test makers must overcome in proving methods for personalized CUP treatment.
The Australia-based firm intends to raise funds in two tranches and use the capital to expand in the US and the UK.
The company offers products and services for analyzing, interpreting, and reporting clinical next-generation sequencing data with a focus on cancer.
Illumina officials discussed several issues with investors, including the new Qiagen partnership, while at ASHG the firm introduced reagent kit upgrades.
In a study published this week, researchers presented a Simoa-based assay for tuberculosis that could ultimately be packaged as a point-of-care test.
Overall growth was driven by growth in sequencing instrument and consumables sales, which offset a 24 percent decline in microarray revenues.
The PCR-based test analyzes mitochondrial DNA to detect prostate cancer in advance of biopsy, independent of prostate-specific antigen levels and age.
The company will test a peptide array approach that it believes can identify MSI-high, immunotherapy-responsive individuals more cheaply and easily than existing tests.
The company's life sciences revenues were up 6 percent while its diagnostics business grew almost 7 percent.
OpGen said it intends to use the proceeds of the offering to complete its acquisition of German molecular diagnostics firm Curetis, among other things.
While the Oxford, UK-based company has focused on drug development partnerships to date, it is also keen to see uptake of genetic disease risk screening by the NHS.
The assay, being developed in partnership with Johnson & Johnson, will complement computed tomography imaging by combining 26 genes and clinical variables for lung cancer detection.
The drug is now approved as a fourth-line option for advanced, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency.
The nonpartisan federal agency's report suggests ways for Congress, the FDA, FTC, and CMS to expand oversight of the genetic testing market.
The companies plan to explore opportunities to use Thermo Fisher's LC-MS instrumentation to develop tools to determine the risk for adverse pregnancy outcomes.
The company delivered organic growth across its four business segments and raised its revenue and earnings guidance for the year.
The company's SpliceCore platform maps patient RNA sequencing data to a collection of over 5 million alternative splicing errors to pinpoint ones that cause disease.
For the three months ended Sept. 30, the firm reported total revenues of $31.0 million, beating analysts' average estimate of $30.1 million.
Diaceutics is projecting that FDA will soon approve more personalized drugs than all-comer drugs, but absent changes in diagnostics strategies many patients won't receive them.
The firm saw 26 percent growth in molecular biology sales, driven in part by 25 percent sales growth for the BioFire FilmArray product line.
In PLOS this week: Mycobacterium abscessus linked to gastric conditions, placental gene expression changes associated with preterm birth, and more.
The Guardian reports that UK universities are looking into ways to reduce labs' reliance on single-use plastics.
People with certain gene variants tend to not like vegetables, particularly bitter ones, CNN reports.
MIT's Technology Review reports on a company's genetic test that gauges an embryo's susceptibility to certain diseases.